Viatris (VTRS) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
PITTSBURGH, Nov. 17, 2026 /PRNewswire/ -- Viatris Inc. ("Viatris") (Nasdaq: VTRS), a global healthcare company, today announced that it has completed its acquisition of Pacira BioSciences, Inc. ("Pacira") (Nasdaq: PCRX), a leader in non-opioid pain management. The transaction was first announced on Oct. 8, 2026.
Multiyear partnership brings together a U.S.-based global healthcare company and America's new Formula 1® team INDIANAPOLIS and PITTSBURGH, Nov. 16, 2026 /PRNewswire/ -- The Cadillac Formula 1® Team and Viatris Inc. (Nasdaq: VTRS), a global healthcare company, today announced a multiyear partnership that makes Viatris the team's Official Global Pharmaceutical Partner, beginning in 2027. The partnership connects motorsport and medicine, two industries where precision, reliability and performance matter.
PITTSBURGH, Nov. 12, 2026 /PRNewswire/ -- Viatris Inc. (Nasdaq: VTRS), a global healthcare company, today announced that it has been named to Fortune's World's Best Workplaces™ list for the second consecutive year, recognizing the Company's commitment to fostering a workplace where colleagues feel valued, supported and empowered to make an impact. The list recognizes 25 global organizations based on Great Place To Work's (GPTW) rigorous assessment process, which includes confidential employee feedback.
PITTSBURGH, Nov. 11, 2026 /PRNewswire/ -- Viatris Inc. (Nasdaq: VTRS), a global healthcare company, today announced that the Company will participate in fireside chats at three upcoming healthcare conferences. The UBS Global Biopharma Conference on November 17, 2026, at 10 a.m.
Investors interested in Medical Services stocks are likely familiar with Viatris (VTRS) and Danaher (DHR). But which of these two stocks presents investors with the better value opportunity right now?